We previously reported a highly selective PROTAC degrader targeting both mSWI/SNF ATPase subunits, SMARCA2 and SMARCA4, demonstrating remarkable therapeutic efficacy in various preclinical models of advanced prostate cancer through intravenous administration (16). This evidence concerns the gene SMARCA2 and prostate carcinoma.